書籍詳細

シンンポジウムI : B型肝炎の治療

P.20 掲載の参考文献

• 1) Ogata N, Miller RH, Ishak KG, et al:The complete nucleotide sequence of a precore mutant of hepatitis B virus implicated in fulminant hepatitis and its biological characterization in chimpanzees. Virology 194:263-276, 1993
  pubmed

• 2) Ogata N, Fujii K, Takigawa S, et al:Novel patterns of amino acid mutations in the hepatitis B virus polymerase in association with resistance to lamivudine therapy in Japanese patients with chronic hepatitis B. J Med Virol 59:270-276, 1999
  pubmed

• 3) 小方則夫, 朝倉 均, 市田文弘:B型慢性肝炎に対するLamivudine長期投与療法およびC型慢性肝炎に対するInterferon-β初期投与療法における抗ウイルス効果と臨床評価. 大学病院における診断と治療シリーズ:肝炎の診断と治療. 東京, 真興交易医書出版, 139-150, 1997

• 4) 小方則夫, 北島 勲, 市田隆文, 他:ラミブジン耐性B型肝炎ウイルス; peptide nucleic acid mediated PCR clamping(PMPC)法によるポリメラーゼYWDDモチーフ塩基変異の高感度検出. 肝臓 42:223-224, 2001

• 5) Poch O, Sauvaget I, Delarue M, et al:Identification of four conserved motifs among the RNA-dependent polymerase encoding elements. EMBO J 8:3867-3874, 1989
  pubmed

• 6) Allen MI, Deslauriers M, Andrews CW, et al:Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology 27:1670-1677, 1998
  pubmed

• 7) Mayers D:Rational approaches to resistance; nucleoside analogues. AIDS 10 (suppl 1):S9-S13, 1996

• 8) Chayama K, Suzuki Y, Kobayashi M, et al:Emergence and turnover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and returnover by wild-type after cessation of therapy. Hepatology 27:1711-1716, 1998

• 9) Kobayashi S, Shimada K, Suzuki H, et al:Development of a new method for detecting a mutation in the gene encoding hepatitis B virus reverse transcriptase active site (YMDD motif). Hepatology Res 17:31-42, 2000

• 10) 岡上 武, 桐島寿彦, 森康二郎, 他:LamivudinによるB型慢性肝炎, 肝硬変の治療-YMDD motif変異ウイルス高感度検出系を用いた検討-. 犬山シンポジウム記録刊行会編. B型肝炎の新しい展開. 東京, アークメディア, 84-89, 2001

• 11) Stuyver L, van Geyt C, de Gendt S, et al:Line probe assay for monitoring drug resistance in hepatitis B virus-induced patients during antiviral therapy. J Clin Microbiol 38:702-707, 2000

P.32 掲載の参考文献

• 1) Coates JAV, Cammack N, Jenkinson HJ, et al:(-)-2'-deoxy-3'thiacytidine is a potent highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vivo. Antimicrob Agents Chemother 35:733-739, 1992

• 2) Lai CL, Liaw YF, Leung NWY, et al:A one year trial of lamivudine for chronic hepatitis B. N Engl J Med 339:61-68, 1998

• 3) Honkoop P, de Man RA, Zondervan PE, et al:Histological improvement in patients with chronic hepatitis B virus infection treated with lamivudine. Liver 17:03-106, 1997
  pubmed

• 4) Suzuki Y, Kumada H, Ikeda K, et al:Histological changes in liver biopsies after one year of lamivudine treatment in patients with chronic hepatitis B infection. J of Hepatology 30:743-748, 1999
  pubmed

• 5) Chayama K, Suzuki Y, Kobayashi M, et al:Emergence and takeover of YMDD motif mutant hepatitis B vius during long-term lamivudine therapy and retakeover by wild type cessation of therapy. Hepatology 27:1711-1715, 1998

P.44 掲載の参考文献

• 1) Ikeda K, Saitoh S, Suzuki Y, et al:Interferon decreases hepatoellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus. Cancer 82:827-835, 1998

• 2) Villeneuve JP, Condreay LD, Willems B, et al:Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology 31:207-210, 2000
  pubmed

• 3) Kapoor D, Guptan RC, Wakil SM, et al:Beneficial effect of lamivudine in hepatitis B virus-related decompensated cirrhosis. J Hepatol 33:308-312, 2000
  pubmed

• 4) 岡上 武:肝硬変に対する抗ウイルス療法. 日消誌 99:139-144, 2002
  Medical*Online

• 5) Chayama K, Suzuki Y, Kobayashi M, et al:Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and retakeover by wild type after cessation of therapy. Hepatology 27:1711-1716, 1998
  pubmed

• 6) Kirishima T, Okanoue T, Daimon Y, et al:A novel sensitive method for the detection of lamivudine-resistant hepatitis B virus polymerase gene variants using peptide nucleic acids (PNA)-mediated PCR-clamping with RFLP. J Hepatol (in press)

• 7) Ono-Nita SK, Kato N, Shiratori Y, et al:YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine-resistance; A study by in vitro full-length viral DNA transfection. Hepatology 29:939-945, 1999
  pubmed

• 8) 0no-Nita SK, Kato N, Shiratori Y, et al:The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J Clin Invest 107:449-455, 2001

• 9) Liaw YF, Leung NW, Chang TT, et al:Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B; Asia Hepatitis Lamivudine Study Group. Gastroenterology 119:172-180, 2000

• 10) Boni C, Bertoletti A, Penna A, et al:Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest 102:968-975, 1998
  pubmed

• 11) Boni C, Penna A, Ogg G, et al:Lamivudine treatment can overcome cytotoxic T cell responsiveness in chronic hepatitis B; New perspective for immune therapy. Hepatology 33:963-971, 2001
  pubmed

• 12) Perrillo R, Schiff E, Toshida E, et al:Adefovir dipivoxil fbr the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 32:129-134, 2000

• 13) de Man RA, Wolter LM, Nevens F, et al:Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection. Hepatology 34:578-582, 2001

P.56 掲載の参考文献

• 1) Ide T, Kumashiro R, Hino T, et al:Transcription-mediated amplification is more useful in the follow-up of patients with chronic hepatitis B treated with lamivudine. Hepatol Res 21:76-84, 2001
  pubmed

• 2) Nafa S, Ahmed S, Tavan D, et al:Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B. Hepatology 32:1078-1088, 2000
  pubmed

• 3) Liu CJ, Chen PJ, Lai MY, et al:Hepatitis B virus variants in patients receiving lamivudine treatment with breakthrough hepatitis evaluated by serial viral loads and full-length viral sequences. Hepatology 34:583-589, 2001
  pubmed

• 4) Ono SK, Kato N, Shiratori Y, et al:The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J Clin Invest 107:449-455, 2001
  pubmed

• 5) 岩永 洋, 加治屋勇二, 大久保和昭, 他:ラミブジン抵抗性B型肝炎ウイルスの出現後に劇症化したB型慢性肝炎の1例. 肝臓 41:660-664, 2000

特別講演I

P.70 掲載の参考文献

• 1) Liaw YF, Tsai SL:Pathogenesis and clinical significance of acute exacerbations and remissions in patients with chronic hepatitis B virus infection. Viral Hep Rev 3:143-154, 1997

• 2) Nicoll A, Locarnini S:Present and future directions in the treatment of chronic hepatitis B infection. J Gastroenterol Hepatol 12:843-854, 19

• 3) Liaw YF:Current trends in therapy for chronic viral hepatitis. J Gastroenterol Hepatol 12:S345-S353, 1997

• 4) Liaw YF, Tai DI, Chu CM, et al:The development of cirrhosis in patients with chronic type B hepatitis:a prospective study. Hepatology 8:493-496, 1988
  pubmed

• 5) Liaw YF, Lin DY, Chen TJ, et al:Natural course after the development of cirrhosis in patients with chronic type B hepatitis:A prospective study. Liver 9:235-241, 1989
  pubmed

• 6) Nair S, Perrillo RP:Serum alanine aminotransferase flares during interferon treatment of chronic hepatitis B:Is sustained clearance of HBV DNA dependent on levels of pretreatment viremia? Hepatology 34:1021-1026, 2001
  pubmed

• 7) Guan R:Interferon monotherapy in chronic hepatitis B. J Gastroenterol Hepatol 15 (Suppl):E34-E40, 2000

• 8) Manesis EK, Hadziyannis SJ:Interferon α treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B. Gastroenterology 121:101-109, 2001

• 9) Cooksley WG, Piratvisuth T, Wang YJ, et al:40 KDA Peginterferon Alfa-2A (PEGASYS(R)):Efficacy and safety results from a phase II, randomized, actively controlled, multicenter study in the treatment of HBeAg positive chronic hepatitis B. Hepatology 34:349A, 200

• 10) Merican I:Treatment of chronic hepatitis B virus infection in special groups of patients:decompensated cirrhosis, immunosuppressed and pediatric patients. J Gastroenterol Hepatol 15 (Suppl):E71-E78, 2000

• 11) Chien RN, Liaw YF, Chen TC, et al:Efficacy of thymosinal in patients with chronic type B hepatitis:a randomized controlled trial. Hepatology 27:1383-1387, 1998

• 12) Lau GKK:Use of immunomodulatory therapy (other than interferon) for the treatment of chronic hepatitis B virus infection. J Gastroenterol Hepatol 15 (Suppl):E46-E52, 2000

• 13) Leung N:Nucleoside analogues in the treatment of chronic hepatitis B. J Gastroenterol Hepatol 15 (Suppl):E53-E60, 2000

• 14) Chien RN, Liaw YF, Atkins M, for Asian Hepatitis Lamivudine Trial Group:Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Hepatology 30:770-774, 1999
  pubmed

• 15) Core working party for Asia-Pacific Consensus on hepatitis B and C:Consensus statements on the prevention and management of hepatitis B and C in the Asia-Pacific region. J Gastroenterol Hepatol 15:825-841, 2000

• 16) Liaw YF, Chien RN, Yeh CT, et al:Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 30:567-572, 1999
  pubmed

• 17) Hadziyannis SJ, Papatheodoridis GV, Dimou E, et al:Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 32:847-851, 2000
  pubmed

• 18) Song BC, Suh DJ, Lee HC, et al:Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 32:803-806, 2000

• 19) Liaw YF, Tsai SL, Chien RN, et al:Prednisolone priming enhances Th1 response and efficacy of subsequent lamivudine therapy in patients with chronic hepatitis B. Hepatology 32:604-609, 2000
  pubmed

• 20) Schalm SW, Heathcote J, Cianciara J, et al:Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection:a randomized trial. Gut 46:562-568, 2000
  pubmed

• 21) Barbaro G, Zechnini F, Pellicelli AM, et al:Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B. An Italian multicenter, randomized trial. J Hepatol 35:406-411, 2001

• 22) Yeh CT, Chen RN, Chu CM, et al:Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy. Hepatology 31:1318-1326, 2000

特別講演II

P.82 掲載の参考文献

• 1) Lee SS, Hadengue A, Girod C, et al:Reduction of intrahepatic vascular space in the pathogenesis of portal hypertension. In vitro and in vivo studies in the rat. Gastroenterology 93:157-161, 1987
  pubmed

• 2) Gupta TK, Chen L, Groszmann RJ:Pathophysiology of portal hypertension. Clin Liv Dis 1:1-12, 1997

• 3) Moreau R, Lebrec D:Endogenous factors involved in the control of arterial tone in cirrhosis. J Hepatol 22:370-376, 1995
  pubmed

• 4) Lebrec D:Pharmacological treatment of portal hypertension:present and future. J Hepatol 28:896-907, 1998
  pubmed

• 5) Hayes PC, Davis J, Lewis JA, et al:Meta-analysis of value of propranolol in prevention of variceal hemorrhage. Lancet 336:153-156, 1990
  pubmed

• 6) Angelico M, Carli L, Piat C, et al:Isosorbide-5-mononitrate versus propranolol in the prevention of first bleeding in cirrhosis. Gastroenterology 104:1460-1465, 1993
  pubmed

• 7) Garcia-Pagan JC, Villanueva C, Vila MC, et al:Isosorbide mononitrate in the prevention of first variceal bleed in patients who cannot receive β-blockers. Gastroenterology 121:908-914, 2001

• 8) Merkel C, Marin R, Enzo E, et al:Randomized trial of nadolol alone or with isosorbide mononitrate fbr primary prophylaxis of variceal bleeding in cirrhosis. Lancet 348:1677-1681, 1996

• 9) Spanish Variceal Bleeding Study Group:Propranolol + placebo vs propranolol + isosorbide-5-mononitrate in the prevention of the first variceal bleeding. A multi-center double-blind randomized controlled trial. J Hepatol 30 (suppl.1):55, 1999

• 10) Pletrosi G, D'Amico G, Pasta L, et al:Isosorbide mononitrate with nadolol compared to nadolol alone for prevention of first bleeding in cirrhosis, a double-blind placebo-controlled randomized trial. J Hepatol 30 (suppl. 1):66, 1999

• 11) Groszmann RJ, Bendsten F, Bosch J, et al:Drug therapy for portal hypertension. In:Portal hypertension ll. Proceedings of the Second Baveno International Consensus Workshop on Definitions, Methodology and Therapeutic Strategies. ed by R. De Franchis. Blackwell Science, Oxford, 98-99, 1996

• 12) Bernard B, Lebrec D, Mathurin P, et al:Beta-adrenergic antagonists in the prevention of gastrointestinal rebleeding in patients with cirrhosis:a meta-analysis. Hepatology 25:63-70, 1997
  pubmed

• 13) Bernard B, Lebrec D, Mathurin P, et al:Propranolol and screrotherapy in the prevention of gastrointestinal rebleeding in patients with cirrhosis:a meta-analysis. J Hepatol 26:312-324, 1997
  pubmed

• 14) Patti R, D'Amico G, Pasta L, et al:Isosorbide mononitrate with nadolol compared to nadolol alone for prevention of recurrent bleeding in cirrhosis. A double-blind placebo-controlled randomized trial. J Hepatol 30 (suppl. 1):81, 1999

シンポジウムII : 門脈圧亢進症の病態と治療

P.96 掲載の参考文献

• 1) 厚生労働省特定疾患門脈血行異常症調査研究班 (杉町圭蔵, 二川俊二, 兼松隆之, 他):門脈血行異常症の診断と治療 (2001年). 肝臓42 (7):378-384, 2001

• 2) 社団法人日本肝臓学会:前がん病変としての肝硬変の動向. 肝がん白書, 平成11年度, 33-37, 1999

• 3) 井口 潔, 小林迪夫, 朔 元則, 他:門脈圧亢進症における門脈循環の特性と食道静脈瘤の成因に関する考察. 肝臓18:891-898, 1977

• 4) Hashizume M, Tanaka K, Inokuchi K:Morphology of gastric microcirculation in cirrhosis. Hepatology 3:1008-1012, 1983
  pubmed

• 5) 0hta M, Hashizume M, Higashi H, et al:Portal and gastric mucosal hemodynamics in cirrhotic patients with portal hypertensive gastropathy. Hepatology 20:1432-1436, 1994

• 6) Shah V, Toruner M, Haddad F, et al:Impaired endothelial nitric oxide synthase activity associated with enhanced caveolin binding in experimenta1 cirrhosis in the rat. Gastroenterology 117:1222-1228, 1999
  pubmed

• 7) Taoue K, Ohta M, Tamawski AS, et al:Portal hypertension activates the nitric oxide synthase genes in the esophageal mucosa of rats. Gastroenterology 110:549-557, 1996

• 8) 0hta M, Tanoue K, Tamawski AS, et al:Overexpressed nitric oxide synthase in portal hypertensive stomach of rat; a key to increased susceptibility to damage? Gastroenterology 112:1920-1930, 1997

• 9) Wiest R, Das S, Cadelina G, et al:Bacterial translocation in cirrhotic rats stimulates eNOS-derived NO production and impairs mesenteric vascular contractility. J Clin Invest 104:1223-1233, 1999
  pubmed

• 10) Lopez-Talavera JC, Merrill WW, Groszmann RJ:Tumor necrosis factor alpha; a major contributer to the hyperdynamic circulation in prehepatic portal hypertensive rats. Gastroenterology 108:761-767, 1995

• 11) Kawanaka H, Jones MK, Szabo IL, et al:Tumor necrosis factor alpha regulates nitric oxide synthase expression in portal hypertensive gastric mucosa of rats. Hepatology 35:393-402, 2002

• 12) Suematsu M, Wakabayashi Y, Ishimura Y:Carbon monoxide as a regulator of bile canalicular contractility in cultured rat hepatocytes. Hepatology 28:286-295, 1998
  pubmed

P.113 掲載の参考文献

• 1) 荒川正博, 野田岳水, 福田一典, 他:食道静脈瘤の臨床病理学的研究-食道壁内血管構築について-. 日消誌80:2339-2346, 1983

• 2) 青木春夫, 藤田順子, 蓮見昭武, 他:門脈下大静脈系巨大シャントと胃静脈瘤との関連;静脈瘤形成関与の3型の提唱. 門脈血行異常症調査研究班 平成5年度報告書:116-119, 1994

• 3) 益崎隆雄:胃穹窿部静脈瘤の臨床病理学的検討-特に胃壁内血管構築について-. 日消誌94:83-91, 1997

• 4) 幕内博康, 町村貴郎, 杉原 隆, 他:食道胃静脈瘤の出血点とその経時的変化. 消化器内視鏡1:1031-1037, 1989

• 5) 日本門脈圧亢進症研究会:食道静脈瘤内視鏡記載基準. 肝臓33:277-281, 1992

P.131 掲載の参考文献

• 1) 高瀬靖広, 岩崎洋治, 南風原英生, 他:内視鏡的食道静脈瘤治療法-とくに手技について-. Progress of Digestive Endoscopy 12:105-108, 1978

• 2) 鈴木博昭, 長尾房夫:内視鏡的硬化療法-手技, 適応, 成績-. 臨床成人病12:2307-2311, 1981

• 3) 幕内博康, 田中 豊, 杉原 隆, 他:食道静脈瘤の内視鏡的硬化療法-ETP法の実際と予後-. 胃と腸20:497-505, 1985

• 4) 小原勝敏, 正木盛夫, 坂本弘明, 他:食道・胃静脈瘤硬化療法におけるEO単独およびEO・AS併用法からみた予後の検討.Gastroenterol Endosc 29:2232-2236, 1987

• 5) Kitano S, Koyanagi N, Iso Y, et al:Prevention of recurrence of esophageal varices after endoscopic injection sclerotherapy with ethanolamine oleate. Hepatology 7:810-815, 1987
  pubmed

• 6) 小原勝敏, 大平弘正, 坂本弘明, 他:食道・胃静脈瘤硬化療法に対するEO・AS併用法の新しい工夫-AS地固め法-. Gastroenterol Endosc 31:2977-2982,1989

• 7) 小原勝敏, 小島俊彦, 入澤篤志, 他:食道静脈瘤に対する地固め法の新しい工夫-Laser地固め法-. Gastroenterol Endosc 36:716-721, 1994

• 8) 村上匡人, 水上祐治, 矢野春海, 他:アルゴンプラズマ凝固法による内視鏡治療の試み. Gastroenterol Endosc 39:1446-1453, 1997

• 9) 入澤篤志, 小原勝敏, 坂本弘明:食道壁外シャントを有する食道静脈瘤に対する硬化療法の静脈瘤造影および超音波内視鏡的検討. 日門食会誌3:147-154, 1997

• 10) 鈴木博昭, 山本 学, 千葉井基泰, 他:Hisoacrylを用いた胃静脈瘤硬化療法. Progress of Digestive Endoscopy 33:83-86, 1988

• 11) 小原勝敏, 大平弘正, 坂本弘明, 他:孤立性胃静脈瘤出血に対するα-cyanoacrylate monomerによる硬化療法の有用性について. Gastroenterol Endosc 31:3209-3216, 1989

• 12) 小原勝敏, 坂本弘明, 滝口藤夫, 他:噴門部静脈瘤 (Lg-c, Lg-cf) 出血に対する緊急・待期硬化療法. 消化器内視鏡3:1435-1443, 1991

• 13) 豊永 純, 小原勝敏, 幕内博康:食道・胃静脈瘤内視鏡治療ガイドライン. 東京, 医学書院, 91-96, 1999

• 14) 小原勝敏:門脈血行動態の把握に基づいた治療法-硬化療法-. Mebio 19 (6):8-15, 2002

• 15) 小原勝敏:食道静脈瘤. 消化器の臨床2:573-585, 1999

• 16) Irisawa A, Obara K, Sato Y, et al:EUS analysis of collateral veins inside and outside the esophageal wall in portal hypertension. Gastrointest Endosc 50:374-380, 1999
  pubmed

• 17) 小原勝敏, 宍戸英夫, 斉藤文子, 他:超音波内視鏡で視る門脈圧亢進症. 消化器内視鏡11:545-553, 1999

• 18) Irisawa A, Saito A, Shibukawa G, et al:Endoscopic recurrence of esophageal varices is associated with the specific EUS abnormarities; severe peri-esophageal collateral veins and large perforating veins. Gastrointest Endosc 53:77-84, 2001
  pubmed

• 19) 斉藤文子, 小原勝敏, 入澤篤志, 他:巨大な食道壁外シャントを有する食道静脈瘤に対する選択的静脈瘤結紮術併用硬化療法の試み, 日門食会誌 3:263-268, 1997

• 20) 小原勝敏, 粕川禮司:食道胃静脈瘤治療の進歩. 最新内科学大系プログレス8 消化管疾患, 中山書店, 99-113, 1997

• 21) 小原勝敏, 粕川禮司:食道・胃静脈瘤の超音波内視鏡診断-硬化療法におけるEUSの意義-. 消化器内視鏡2:1395-1403, 1990

• 22) 村松雅彦, 本田泰啓, 小泉雅紀, 他:予後からみた予防的胃静脈瘤硬化療法の是非-硬化療法非施行例との検討. 日門食会誌4:249-253, 1998

• 23) 小原勝敏:最も優れた胃静脈瘤治療とは. 日門食会誌5:3-5, 1999

• 24) 入澤篤志, 小原勝敏, 斉藤文子, 他:孤立性胃静脈瘤に対する予防内視鏡的硬化療法の適応-出血と再発の予知. 日門食会誌4:229-234, 1998

• 25) 林 星舟, 佐伯俊一, 鶴田浩二:胃宥隆部静脈瘤に対する予防的治療の評価. 日門食会誌4:222-228, 1998

• 26) 深沢正樹, 中西 亮, 児島邦明, 他:胃静脈瘤に対するHassab手術成績の検討. 日門食会誌4:235-240, 1998

• 27) 金川博史, 美馬聰昭, 香山明一, 他:バルーン逆行性経静脈的塞栓術 (Balloon-occluded retrograde transvenous obliteration) による胃静脈瘤の1治験例. 日消誌88:1459-1462, 1991

• 28) 小原勝敏, 入澤篤志, 斉藤文子, 他:胃静脈瘤の内視鏡的治療. Mebio 15:68-77, 1998

• 29) 小原勝敏, 入澤篤志, 小島俊彦, 他:瞬間接着剤cyanoacrylate. 消化器内視鏡7:43-53, 1995

• 30) 小原勝敏:胃静脈瘤の内視鏡治療 (B-RTOも含む). 消化器病セミナー 78. へるす出版, 97-110, 2000

• 31) 入澤篤志, 小原勝敏, 粕川禮司:EUSによる治療法の選択と治療効果判定. 鈴木博昭監, 食道・胃静脈瘤. 東京, 日本メディカルセンター, 197-204, 1996

• 32) 落合浩暢, 小原勝敏, 東條 淳, 他:胃静脈瘤硬化療法における超音波内視鏡の有用性についての検討-静脈瘤径からみた硬化剤の選択. Gastroenterol Endosc 39:191-198, 1997

• 33) Irisawa A, Obara K, SatO Y, et al:Adherence of Cyanoacrylate which Leaked from Gastric Varices to the Left Renal Vein During Endoscopic Injection Sclerotherapy; A Histopathologic Study. Endoscopy 32:804-806, 2000

• 34) 斉藤文子, 小原勝敏, 入澤篤志, 他:孤立性胃静脈瘤に対する新しい治療手技の工夫-Lg地固め法-. 消化器研究の新たな進歩vol.3:55-58, 1998

• 35) 斉藤文子, 入澤篤志, 小原勝敏, 他:食道・胃静脈瘤に対する地固め法. 消化器科33 (2):118-125, 2001

P.144 掲載の参考文献

• 1) Lebrec D, Poynard T, Hillon P, et al:Propranolol for prevention of recurrent gastro-intestinal bleeding in patients with cirrhosis; A controlled study. N Engl J Med 305:1371-1374, 1981
  pubmed

• 2) D'Amico G, Pagliaro L, Bosch J:Pharmacological treatment of portal hypertension; an evidence-based approach. Semin Liver Dis 19:475-505, 1999

• 3) Bosch J, Garcia-Pagan JC:Complication of cirrhosis. I. Portal hypertension. J Hepatol 32:141-156, 2000
  pubmed

• 4) Bariares R, Albillos A, Rincon D, et al:Endoscopic treatment versus endoscopic plus pharmacologic treatment for acute variceal bleeding;meta-analysis. Hepatology 35:609-615, 2002

• 5) Aramaki T, Sekiyama T, KatSuta Y, et al:Long-term haemOdynamic effects of a 4-week regimen of nipradilol, a new-β-blccker with nitrovasodilating propenies, in patients with portal hypertension due to cirrhosis;A comparative study with propranolol. J Hepato 115:48-53, 1992

• 6) Sugano S, Kawafune T, Suzuki T, et al:0ral administration of nipradilol and the acute and chronic splanchnic hemodynamic effects of a new β-blccker with nitrova-sodilating propenies in patients with liver cirrhosis. Am J Gastroenterol 90:788-793, 1995

• 7) Sugano S, Suzuki T, Nishio M, et al:Chronic splanchnic hemodynamic effects of low-dose transdermal nitroglycerin versus low-dose transdermal nitroglycerin plus spironolactone in patients with cirthosis. Dig Dis Sci 42:529-535, 1997
  pubmed

• 8) Sugano S, KawafUne T, Okaj ima T, et al:Chronic splanchnic hemodynamic effects of spironolactone with an unrestricted sodium diet in patients with compensated cirrhosis. Dig Dis Sci 43:893-897, 1998

• 9) Iwao T, Oho K, Sakai T, et al:Noninvasive hemOdynamic measurements of superior mesenteric artery in the prediction of portal pressure response to propranolol. J Hepato128 (5):847-855, 1998
  pubmed

• 10) Schepke M, Raab P, Hoppe A, et al:Comparison of portal vein velocity and the hepatic venous pressure gradient in assessing the acute portal hemodynamic response to propranolol in patients with cirrhosis. Am J Gastroenterol 95 (10):2905-2909, 2000
  pubmed

• 11) Sugano S, Yamamoto K, Sasao K, et al:Daily variation of azygos and portal blood flow and the effect of propranolol administration once an evening in cirrhotics. J Hepatol 34:26-31, 2001
  pubmed

• 12) Lo GH, Lai KH, Cheng JS, et al:Endoscopic variceal ligation plus nadolol and sucralfate compared with ligation alone for the prevention of variceal rebleeding;a prospective, randomized trial. Hepatology 32 (3):461-465, 2000
  pubmed

• 13) Sugano S, Nishio M, Makino H, et al:Relationship of portal pressure and colorectal vasculopathy in patients with cirrhosis. Dig Dis Sci 44:149-154, 1999
  pubmed